CO5680458A2 - THE COMBINATION OF A SEROTONINE REABSORTION INHIBITOR AND A TYPE 1 GLICINE TRANSPORTER INHIBITOR FOR DEPRESSION TREATMENT - Google Patents
THE COMBINATION OF A SEROTONINE REABSORTION INHIBITOR AND A TYPE 1 GLICINE TRANSPORTER INHIBITOR FOR DEPRESSION TREATMENTInfo
- Publication number
- CO5680458A2 CO5680458A2 CO06016118A CO06016118A CO5680458A2 CO 5680458 A2 CO5680458 A2 CO 5680458A2 CO 06016118 A CO06016118 A CO 06016118A CO 06016118 A CO06016118 A CO 06016118A CO 5680458 A2 CO5680458 A2 CO 5680458A2
- Authority
- CO
- Colombia
- Prior art keywords
- disorder
- inhibitor
- disorders
- anxiety
- serotonin reuptake
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- El uso de un compuesto, que es un inhibidor de reabsorción de serotonina, y un compuesto, que es un inhibidor de GlyT-1 para la preparación de una composición farmacéutica para el tratamiento de depresión, trastornos de ansiedad y otros trastornos afectivos, tales como trastorno de ansiedad generalizada, ansiedad de pánico, trastorno compulsivo obsesivo, trastorno de estrés agudo, trastorno de estrés post-traumático y trastorno de ansiedad social, trastornos de la alimentación tales como bulimia, anorexia y obesidad, fobias, distimia, sindrome premenstrual, trastornos cognoscitivos, trastornos de control del impulso, trastorno de hiperactividad de déficit de atención, abuso de drogas o cualquier otro trastorno que responda a inhibidores de reabsorción de serotonina.2.- El uso de un inhibidor de GlyT-1 para la preparación de una composición farmacéutica a ser utilizada en combinación con un inhibidor de reabsorción de serotonina.3.- El uso de un inhibidor de GlyT-1 para la preparación de una composición farmacéutica útil para aumentar y / o proporcionar comienzo más rápido del efecto terapéutico de un inhibidor de reabsorción de serotonina.4.- El uso de acuerdo con una cualquiera de las reivindicaciones 2-3, en el cual el inhibidor de reabsorción de serotonina es utilizado para el tratamiento de depresión, trastornos de ansiedad y otros trastornos afectivos, incluyendo trastorno de ansiedad generalizada, ansiedad de pánico, trastorno compulsivo obsesivo, trastorno de estrés agudo, trastorno de estrés post-traumático o trastorno de ansiedad social, trastornos de la alimentación tales como bulimia, anorexia y obesidad, fobias, distimia, sindrome premenstrual, trastornos cognoscitivos, trastornos de control del impulso, trastorno de hiperactividad de déficit de atención, abuso de drogas o cualquier otro trastorno que responda a un SRI.5.- El uso de acuerdo con una cualquiera de las reivindicaciones 1-4, en el cual el SRI es seleccionado de un SSRI.1.- The use of a compound, which is a serotonin reuptake inhibitor, and a compound, which is a GlyT-1 inhibitor for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders. , such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post-traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, syndrome premenstrual, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder that responds to serotonin reuptake inhibitors.2.- The use of a GlyT-1 inhibitor for preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor. 3.- The use of a GlyT-1 inhibitor. for the preparation of a pharmaceutical composition useful for increasing and / or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor. 4. The use according to any one of claims 2-3, wherein the inhibitor Serotonin resorption is used for the treatment of depression, anxiety disorders and other affective disorders, including generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post-traumatic stress disorder or social anxiety disorder , eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder that responds to a SRI. 5. The use according to any one of claims 1-4, wherein the SRI is selected Waving of an SSRI.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200301198 | 2003-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5680458A2 true CO5680458A2 (en) | 2006-09-29 |
Family
ID=58707234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO06016118A CO5680458A2 (en) | 2003-08-21 | 2006-02-17 | THE COMBINATION OF A SEROTONINE REABSORTION INHIBITOR AND A TYPE 1 GLICINE TRANSPORTER INHIBITOR FOR DEPRESSION TREATMENT |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR045284A1 (en) |
| CO (1) | CO5680458A2 (en) |
| EA (1) | EA200600453A1 (en) |
| IL (1) | IL173825A0 (en) |
| ZA (1) | ZA200601084B (en) |
-
2004
- 2004-08-18 ZA ZA200601084A patent/ZA200601084B/en unknown
- 2004-08-18 EA EA200600453A patent/EA200600453A1/en unknown
- 2004-08-19 AR ARP040102976A patent/AR045284A1/en not_active Application Discontinuation
-
2006
- 2006-02-17 CO CO06016118A patent/CO5680458A2/en not_active Application Discontinuation
- 2006-02-20 IL IL173825A patent/IL173825A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA200600453A1 (en) | 2006-08-25 |
| IL173825A0 (en) | 2006-07-05 |
| ZA200601084B (en) | 2007-04-25 |
| AR045284A1 (en) | 2005-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124111T1 (en) | GLUTAMATE REGULATORS IN THE TREATMENT OF MENTAL DISORDERS | |
| BR112017015773A2 (en) | lipocalin mutein, hngal mutein, nucleic acid molecule, host cell, method for producing hngal mutein, pharmaceutical composition, kit, use of hngal mutein, use of hngal mutein, method for binding ang-2 in an individual , method for inhibiting angiogenesis in an individual, method for treating, preventing or ameliorating a disease, and method for inhibiting or reducing angiogenesis in an individual | |
| CL2008002916A1 (en) | Compounds derived from triazolopyridine, 11-beta-hydroxysteroid dehydrogenase type I inhibitors; pharmaceutical composition comprising them; and its use in the treatment and / or prevention of diabetes, dyslipidemia, obesity, among others. | |
| DE60200492D1 (en) | Combination of an inhibitor of serotonin reuptake and an atypical antipsychotic for the treatment of depression, obsessive compulsive disorder and psychosis | |
| CO6640335A2 (en) | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity or prediabetes | |
| AR033308A1 (en) | USE OF ENANTIOMERICALLY PURE SCITALOPRAM | |
| CL2022001178A1 (en) | tyk2 pseudokinase ligands | |
| MX2023013040A (en) | Compositions and methods for the treatment of depression. | |
| CL2022002990A1 (en) | Macrocyclic inhibitors of peptidylarginine deiminases | |
| BRPI0617382A2 (en) | METHODS FOR TREATMENT OF A DISORDER OF THE CENTRAL NERVOUS SYSTEM IN A PATIENT, FOR TREATMENT FOR A PATIENT SUFFERING FROM CONDITIONS AND A SEXUAL DYSFUNCTION, AND FOR REDUCING A DELAY IN THERAPEUTIC EFFECTIVENESS FOLLOWING INITIATION OF TREATMENT | |
| JP2007513052A5 (en) | ||
| AR047715A1 (en) | ANALEPTIC AND ANTDEPRESSIVE COMBINATIONS | |
| NO20061167L (en) | The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | |
| CO5680458A2 (en) | THE COMBINATION OF A SEROTONINE REABSORTION INHIBITOR AND A TYPE 1 GLICINE TRANSPORTER INHIBITOR FOR DEPRESSION TREATMENT | |
| NO20061425L (en) | The combination of a serotonin reuptake inhibitor and loxapine | |
| DK1545552T3 (en) | Combination therapy using a serotin reuptake inhibitor | |
| AR045423A1 (en) | COMBINATIONS OF ANALYTICS AND ANTIDEPRESSANTS | |
| AR045314A1 (en) | PHARMACEUTICAL COMPOSITIONS OF ANALEPTICS AND ANTIDEPRESSANTS | |
| AR047716A1 (en) | ANALEPTIC AND ANTIDEPRESSIVE COMBINATIONS | |
| NO20082201L (en) | Stable pharmaceutical formulations containing escitalopram and bupropion | |
| CO5680440A2 (en) | COMBINATION THERAPY WHERE A SEROTONINE RECOVERY INHIBITOR IS USED | |
| AR048134A1 (en) | THE COMBINATION OF AN INHIBITOR OF THE RECOVERY OF SEROTONINE AND AN ANTAGONIST OF THE RECEIVER OF HISTAMINE 3, THE INVESTED AGONIST OR THE PARTIAL AGONIST | |
| CY1112216T1 (en) | RELATIVE COMBINATION OF MEDICINAL SUBSTANCES AS ANTI-DEPARTMENT | |
| AR056056A1 (en) | ASSOCIATION BETWEEN AGOMELATIN AND AN INHIBITOR OF THE RECOVERY OF NORADRENALINE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| EA201390532A1 (en) | COMPOSITIONS OF NS3 SULFAMIDE INHIBITORS CONTAINING VITAMIN E |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |